GSK herpes vaccine trial fails Phase I/II efficacy objective

Vaccine candidate will not progress to Phase III (Il Sole 24 Ore Radiocor) - London, 11 Sep - The UK pharmaceutical company GSK said that results from the phase I/II part of the TH HSV REC-003 trial to assess the potential clinical efficacy of GSK3943104, an early-stage therapeutic herpes simplex virus (HSV) vaccine candidate, did not meet the primary efficacy objective and therefore, it will not progress to Phase III studies.

The TH HSV REC-003 study will continue for routine safety monitoring and to generate follow-up data that could offer valuable insights into recurrent genital herpes, the company said.

AAA-Sch

(RADIOCOR) 11-09-24 10:21:30 (0228) 5 NNNN